Relapsed/Refractory Multiple Myeloma

Oncology·MeSH: Multiple Myeloma

Prevalence

17.0 / 100K

Incidence

7.0 / 100K/yr

23 drugs in development·12 companies·14 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Phase 2(1)

Drug	Company
allo-715	Allogene Therapeutics, Inc. (ALLO)

Phase 1(10)

Drug	Company
ABT-199	AbbVie Inc. (ABBV)
CLN-619	Cullinan Therapeutics, Inc. (CGEM)
diphenhydramine	Sanofi (SNY)
Efbalropendekin alfa (XmAb306 / RG6323)	Xencor Inc (XNCR)
mk-4002	Merck & Co., Inc. (MRK)
nirogacestat	Allogene Therapeutics, Inc. (ALLO)
nxc-201	Immix Biopharma, Inc. (IMMX)
sar445514	Sanofi (SNY)
sar445514	Sanofi (SNYNF)
sti-1492	Sorrento Therapeutics, Inc. (SRNE)

Unknown(1)

Drug	Company
LCAR- F33S cells intravenous infusion	Legend Biotech Corp (LEGN)

Phase 1/Phase 2(4)

Drug	Company
Carfilzomib	BeOne Medicines Ltd. (ONC)
daratumumab	BeOne Medicines Ltd. (ONC)
Daratumumab	BeOne Medicines Ltd. (ONC)
regn7945+linvoseltamab	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 4(1)

Drug	Company
tocilizumab	REGENERON PHARMACEUTICALS, INC. (REGN)

BioSniper tracks 23 drugs in development for Relapsed/Refractory Multiple Myeloma across 12 companies.

There are 14 clinical trials targeting Relapsed/Refractory Multiple Myeloma tracked by BioSniper.

The estimated prevalence of Relapsed/Refractory Multiple Myeloma is approximately 17.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.